A Mumps Outbreak in Vojvodina, Serbia, in 2012 Underlines the Need for Additional Vaccination Opportunities for Young Adults by Nedeljković, Jasminka et al.
RESEARCH ARTICLE
A Mumps Outbreak in Vojvodina, Serbia, in
2012 Underlines the Need for Additional
Vaccination Opportunities for Young Adults
Jasminka Nedeljković1, Vesna Kovačević-Jovanović1, Vesna Milošević2, Zorica Šeguljev2,
Vladimir Petrovic2, Claude P. Muller3*, Judith M. Hübschen3
1 Institute of Virology, Vaccine and Sera "Torlak", Belgrade, Serbia, 2 Institute of Public Health of Vojvodina,
Centre for Disease Control and Prevention, Novi Sad, Serbia, 3 Department of Infection and Immunity,
WHO-EURO Regional Reference Laboratory for Measles and Rubella, Luxembourg Institute of Health




In 2012, mumps was introduced from Bosnia and Herzegovina to Vojvodina, causing an
outbreak with 335 reported cases. The present manuscript analyses the epidemiological
and laboratory characteristics of this outbreak, identifies its main causes and suggests
potential future preventive measures. Sera of 133 patients were tested for mumps-specific
antibodies by ELISA and 15 nose/throat swabs were investigated for mumps virus RNA by
RT-PCR. IgG antibodies were found in 127 patients (95.5%). Mumps infection was labora-
tory-confirmed in 53 patients, including 44 IgM and 9 PCR positive cases. All other 282
cases were classified as epidemiologically-confirmed. More than half of the patients (n =
181, 54%) were 20–29 years old, followed by the 15–19 age bracket (n = 95, 28.4%). Twice
as many males as females were affected (67% versus 33%). Disease complications were
reported in 13 cases (3.9%), including 9 patients with orchitis and 4 with pancreatitis.
According to medical records or anamnestic data, 190 patients (56.7%) were immunized
with two doses and 35 (10.4%) with one dose of mumps-containing vaccine. The Serbian
sequences corresponded to a minor genotype G variant detected during the 2011/2012
mumps outbreak in Bosnia and Herzegovina. Vaccine failures, the initial one-dose immuni-
zation policy and a vaccine shortage between 1999 and 2002 contributed to the outbreak.
Additional vaccination opportunities should be offered to young adults during transition peri-
ods in their life trajectories.
Introduction
Mumps is a contagious vaccine-preventable disease, caused by mumps virus (MuV), a member
of the family Paramyxoviridae. The disease is generally mild, but in some cases can be associ-
ated with complications such as orchitis, encephalitis and deafness [1].
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In Serbia, mumps has been a notifiable disease since 1978. Immunisation against mumps
using measles-mumps (MM) vaccine was introduced in the childhood immunization schedule
in 1986 (L-Zagreb strain; vaccine produced by the Institute of Immunology Zagreb). Since
1993 measles/mumps/rubella (MMR) vaccine, containing Urabe AM9 vaccine strain (mainly
TRIMOVAXMÉRIEUX vaccine from Sanofi Pasteur), is used. An exception were the years
2001 and 2002 when the Jeryl Lynn strain in the Glaxo SmithKline MMR vaccine was applied.
A two-dose schedule, with the first dose given at 12 months and the second at 12 years and no
later than 14 years of age, was introduced in 1996. Since 2006, the second dose is administered
at the age of 7 years [2].
In the Autonomous Province (AP) Vojvodina a large mumps outbreak occurred in 1988
with an incidence of 847 cases per 100,000 inhabitants [3]. This outbreak resulted in an
increase of natural herd immunity in the population and a drastic decline in mumps incidence
during the first few years of the immunization period. Between 1997 and 2006, the vaccination
coverage for the first dose ranged from 82.1% to 98.1% with an average of 95.0%; the coverage
for the second dose of mumps-containing vaccine ranged from 53.2% to 98.8% with an average
of 87.1% [4]. The lowest second-dose coverage rates were recorded in 2002 (53.2%) and 2000
(62.0%), since between 1999 and 2002 there was a vaccine shortage all over Serbia due to
importation problems. From 2003 until the outbreak in 2012, MMR coverage was continuously
above 95% for both doses [5].
In 2012 a mumps outbreak involving 335 cases until the end of June occurred in AP Vojvo-
dina. The present manuscript analyses the epidemiological and laboratory characteristics of
this outbreak, identifies its main causes and suggests potential future preventive measures.
Materials and Methods
Ethics Statement
The physicians at the health centers were responsible for the clinical diagnosis of the parotitis
cases. The investigation of this outbreak was done in the frame of non-research national public
health surveillance for mumps and did not comprise any previously planned activities that
could have been reviewed by an ethics committee or institutional review board. Sample collec-
tion was done for laboratory diagnosis as part of standard patient care and did therefore not
require written informed consent. Clinical specimens were collected only if the patient pro-
vided oral consent.
The epidemiological staff of the Public Health Service of Vojvodina recorded patient data
including date of birth, gender, place of residence, clinical symptoms, date of symptom onset,
immunization status and disease complications. Data were reported on a weekly basis from the
health centers to the Public Health Service of Vojvodina where descriptive epidemiological meth-
ods were used to process, evaluate and analyze all available patient data. Access to patient data
was restricted to people directly involved in diagnosis and reporting to the treating physician.
Case Definitions
According to the WHO criteria, a clinical case in the 2012 mumps outbreak was defined as a
person with acute onset of unilateral or bilateral tender, self-limited swelling of the parotid or
other salivary gland, lasting two or more days without other apparent cause [6]. A laboratory-
confirmed case was defined as a clinical case of parotitis confirmed serologically and/or by
molecular techniques. An epidemiologically confirmed case meets the clinical case definition
and has an epidemiological link to a laboratory-confirmed case [6]. An imported case of
mumps was defined as a clinical case epidemiologically linked to a mumps case in Bosnia and
Herzegovina within the maximum length of the incubation period and an import-related case
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was defined as a person meeting the clinical criteria who has a direct epidemiological link to an
imported case of mumps.
Patient Samples
Serum samples from 133 patients presenting with parotitis were collected 1–14 days after the
onset of disease for serological diagnosis. Convalescent sera were obtained from 10 patients
7–14 days following the first serum sample. For molecular analysis nose/throat swabs were col-
lected from 15 patients 1–5 days after disease onset and from 13 of these patients also serum
samples were available for antibody detection (Fig 1).
Serology
Sera of 133 patients were tested at the Institute of Public Health of Vojvodina. Determination
of MuV specific IgM and IgG antibodies was done using EUROIMMUN AG IgM and IgG
Fig 1. Testing algorithm of clinical samples.
doi:10.1371/journal.pone.0139815.g001
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assays (Lübeck, Germany) according to the manufacturer’s instructions. The sera of the 13
patients of whom also nose/throat swabs were available, were investigated at Institute Torlak
using Enzygnost anti-parotitis virus IgM and IgG kits (Siemens, Marburg, Germany) according
to the manufacturer’s instructions.
Molecular Diagnosis
Detection of MuV RNA was done by Real-time PCR at Institute Torlak. RNA was extracted
from nose/throat samples using a QIAamp viral RNA kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s instructions. For MuV detection a Real-time PCR was done using a
Qiagen one-step RT-PCR kit (Hilden, Germany) and primers and probes provided by the Sta-
tens Institute, Denmark (MP1- f: 5'- CATAGGRGAYATGTGGGGACCAACCATT-3’; MP2 –
r: 5'- GTCTTCGCCAACGATGGTGATGATTG-3’; MP probe: 5'-FAM-CCATGCAGGC
GGTCACATTCCRACAACTGC-TAMRA-3’, Nielsen LP, Department of Microbiological
Diagnostics and Virology, 2009, unpublished). PCR amplification of the SH gene region,
sequencing, genotype determination and phylogenetic analysis were done at the WHO Euro-
pean Regional Reference Laboratory for Measles and Rubella in Luxembourg as described




The outbreak started with two mumps cases registered in Novi Sad, Serbia on 16th January
2012 among students who had spent the Christmas and New Year holidays in Bosnia and Her-
zegovina, where a large outbreak of mumps was ongoing at that time [7,8]. The week after,
another 15 cases who had spent their holidays in Bosnia and Herzegovina were notified. Subse-
quently, mumps spread from the imported cases to the population of Novi Sad. On January 25,
the Public Health Service started to report mumps cases among persons living, working or
studying in Novi Sad. These patients had not travelled outside the city during the maximum
length of the incubation period [9], but were epidemiologically linked to imported mumps
cases and thus considered as import-related cases. Eventually, the infection spread to other
parts of the AP Vojvodina. The outbreak peaked between calendar weeks 11 and 14. By the end
of June (week 26), 335 clinical mumps cases had been registered, among them 25 imported and
32 directly import-related cases. Although the main wave of the epidemic was over by June 30,
24 additional sporadic cases from other parts of Vojvodina were registered until the end of
2012. Disease complications were specifically reported only early during the outbreak in 13
patients (3.9%), including 9 patients with orchitis and 4 with pancreatitis.
Of the 335 mumps cases, 225 (67%) were male and 110 (33%) were female (Fig 2). The age
of the patients ranged between 4 and 58 years (mean 21.6 years). More than half of the patients
(n = 181, 54%) were between 20 and 29 years old (Fig 2). The overall mumps incidence in AP
Vojvodina was 17.3 per 100 000 inhabitants. The age-specific incidence rates ranged from 0.7
(age40 years) to 86.5 (age 15–19 years) per 100 000.
Information about previous vaccinations was obtained from medical records in the health
facilities (n = 196, 58.5%) or if unavailable from anamnestic data (n = 139, 41.5%). The medical
records of students not originating in AP Vojvodina were kept in the health centers of their
places of origin and the anamnestic data were in part collected by phone conversation of the
students with their parents.
According to the medical records, a total of 169 patients had been vaccinated with two
doses of MMR or MM vaccine and 27 with one dose (between 1986 and 1996 immunization
Mumps Outbreak in Serbia in 2012 and Vaccination Needs
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was carried out with only one dose of mumps-containing vaccine). Among the 139 patients
without records, 21 specified that they were immunized with two doses, 8 with one dose, 62
declared they had not received any mumps vaccine and 48 reported an unknown immuniza-
tion status. Thus, 190 patients (56.7%) in total were considered immunized with two doses and
35 (10.4%) with one dose of mumps-containing vaccine; 62 (18.5%) had not received mumps
vaccine and 48 (14.3%) had an unknown vaccination status. The majority of the patients with
medical records and two doses of vaccine were between 15 and 29 years old (n = 157, 92.9%),
while most of the patients with a single dose were between 20 and 29 years old (n = 20, 74.1%,
Fig 3).
Countermeasures
The public health authorities of AP Vojvodina recommended that the vaccination records of
all children between one and 14 years of age should be checked and children who had not yet
received the recommended MMR vaccine should be immunized. The public health authorities
disseminated information about the mumps outbreak, infected persons were isolated as much
as possible and people who had been in contact with mumps patients were placed under medi-
cal surveillance [9].
Laboratory Findings
Mumps-specific IgM antibodies were detected in 44 out of 133 patients (33.1%), while IgG
antibodies were found in 127 patients (95.5%). The highest proportion of IgM positives was
detected among patients of at least 30 years of age (Fig 4).
In 2 of the 10 patients with convalescent serum, mumps-specific IgM antibodies were
detected at the second collection time point (patient 7 absorbance value 5,45 and patient 10
absorbance value 1,12). All patients were already IgG positive at the initial testing and did not
Fig 2. Number of mumps cases reported in Vojvodina between January and June 2012 according to
age group and gender.
doi:10.1371/journal.pone.0139815.g002
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show a significant rise of antibody titers in the follow-up sample (Fig 5). No samples for PCR
investigation were available from the 8 IgM negative patients.
Mumps-specific IgM antibodies were detected in 4 out of the six patients with orchitis tested
(Table 1). Three of these IgM positive patients were unvaccinated and one had received a single
dose of vaccine. The two investigated cases with pancreatitis were IgM negative and IgG posi-
tive (Table 1). All three patients vaccinated with two doses of mumps-containing vaccine were
IgM negative, but IgG positive.
Fig 3. Mumps vaccination status of 335 cases reported in Vojvodina between January and June 2012
according to age group.
doi:10.1371/journal.pone.0139815.g003
Fig 4. Serological status of 133 mumps patients reported in Vojvodina between January and June
2012 according to age group.
doi:10.1371/journal.pone.0139815.g004
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Mumps virus RNA was detected in 9 of 15 patients (60%, Table 2). All PCR positive patients
for whom serology results were available were IgM negative and IgG positive. Four RNA posi-
tive patients had been vaccinated with two doses, 2 had been vaccinated with one dose, another
2 had an unknown vaccination status and 1 patient had not received any mumps-containing
vaccine.
Overall, mumps infection was laboratory confirmed in 53 cases, including 44 IgM positive
and 9 PCR positive cases. All other mumps cases were classified as epidemiologically confirmed
(Table 3).
According to the medical records and anamnestic data, 16 of these 53 patients (30.2%) had
been immunized with two doses and 6 (11.3%) with one dose of mumps-containing vaccine
(Fig 6). Especially among the 20–39 year-old laboratory-confirmed cases were many with
unknown vaccination status (n = 17) or not vaccinated (n = 13, Fig 6).
Amplification and sequencing of the mumps virus SH gene was successful for 8 of the 9
samples positive in the diagnostic PCR. All sequences were identical in the 316 nucleotide
region used for genotyping (except for sequence MuVs/Novi Sad.SRB/3.12 showing a Y instead
of a T at position 28) and corresponded to a minor genotype G variant detected during the
mumps outbreak in Bosnia and Herzegovina (MuVs/Sarajevo.BIH/3.12/3, HF912221). No
other identical sequences were identified using BLAST.
Discussion
Despite a considerable reduction in mumps cases following the introduction of two-dose
immunization programs, outbreaks continue to occur throughout Europe [7,8,10–12]. Unlike
during the prevaccination period when mostly 5 to 9 year old children were affected, today
mumps develops mainly in adolescents and adults, vaccinated or not during childhood [13,14].
Also in the present outbreak the most affected were the 15 to 29 year olds. The 20 to 29 year
old people were supposed to get their first dose of vaccine between 1984 and 1993. However,
vaccination against mumps started in Serbia only in 1986 and until 1996 included only a single
dose of mumps-containing vaccine. Due to vaccine shortage between 1999 and 2002
Fig 5. Mumps-specific IgG antibody absorbance values of 10 patients with convalescent sera from
Vojvodina reported between January and June 2012.
doi:10.1371/journal.pone.0139815.g005
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throughout Serbia, coverage rates especially of the second dose dropped considerably and
affected people who at that time were 12 years old and during the current outbreak between 22
and 25 years old. On the other hand, the majority of the adolescents and young adults with
medical records (96.4% of the 15–19 and 79.4% of the 20–29 year olds) had received two doses
of mumps vaccine (Fig 3). While this is in contrast to a recent mumps outbreak in Bosnia and
Herzegovina where most of the reported cases were of similar age, but were not vaccinated or
had an unknown vaccination history [7,8], mumps outbreaks in vaccinated populations have
been described before [14–16]. Besides primary vaccine failures characterized by a lack of IgG
antibody production, secondary vaccine failures with waning of antibodies and immunity have
been reported [17,18]. Some authors observed a decline in protection with increasing age, but
after 2 doses, vaccine effectiveness was reported to be above 85% even 6–7 years after the sec-
ond vaccination [18]. It has been suggested that mumps manifests especially in cohorts which
had received the latest (second) dose more than 10 years before [15]. This was the case for
Table 1. Age, vaccinal status and serology results of 9 mumps patients with complications reported from Vojvodina between January and June
2012.
Patient Complication Age (in year) Vaccinal status IgM IgG
11 orchitis 29 I dose + +
12 orchitis 20 non immunized + +
13 orchitis 18 II doses -a + a
14 orchitis 25 II doses - +
15 orchitis 32 non immunized + a + a
16 orchitis 28 non immunized + +
17 orchitis 37 non immunized not done not done
18 pancreatitis 19 II doses - +
19 pancreatitis 20 unknown - +
a paired serum samples, results relate to second serum
doi:10.1371/journal.pone.0139815.t001
Table 2. Laboratory results and characteristics of 15 mumps patients with specimens for molecular detection.
Patient Age (in years) Days between symptom onset and sample collection ELISA results Real-time PCR Vaccination status
20 21 1 IgM-, IgG+ positive two doses
21 20 2 IgM-, IgG+ positive one dose
22 21 2 IgM-, IgG+ positive unknown
23 21 2 IgM-, IgG+ positive unknown
24 28 3 IgM-, IgG+ negative two doses
25 22 4 IgM-, IgG+ negative two doses
26 21 2 IgM-, IgG+ positive two doses
27 4 3 IgM-, IgG+ negative unknown
28 20 no data IgM-, IgG+ negative two doses
29 25 3 IgM-, IgG+ positive unvaccinated
30 21 no data IgM-, IgG eva negative unknown
31 32 no data not done negative unknown
32 7 2 IgM-, IgG+ positive two doses
33 21 2 IgM-, IgG+ positive two doses
34 22 3 not done positive one dose
a equivocal
doi:10.1371/journal.pone.0139815.t002
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people older than 22 years at the time of the outbreak in Vojvodina. Compared to other Euro-
pean countries, Serbian children were with 12 years older when they received the second vac-
cine dose. Although this may be considered an advantage, it has been reported that mean
antibody titers were somewhat lower before and after revaccination of 11- to 13-year-old chil-
dren compared to the 4 to 6-year-olds [19].
In the present study, 41.5% of 53 laboratory confirmed mumps cases had been vaccinated,
16 patients with two doses and 6 patients with a single dose. Booster immune responses in
patients with mumps secondary vaccine failure have been reported before [20] and we also
observed high levels of mumps IgG antibodies in the six previously vaccinated RNA positive
patients. While some of the IgM negative results may be explained by the partly early collection
time point after symptom onset, our results showed, similar to reports from many other
authors [21–23], that specific IgM antibodies are an unreliable marker of mumps infection in
highly vaccinated populations. RNA detection proved helpful to confirm mumps in IgM nega-
tive patients with clinical parotitis. The overall low number of RNA positives in the present
study could be due to inadequate sample collection and the storage of the swabs at -20°C before
transportation to the laboratory.
Table 3. Classification of all 335 mumps cases reported from Vojvodina between January and June
2012.





*no IgM positives among them
doi:10.1371/journal.pone.0139815.t003
Fig 6. Immunization status of 53 laboratory confirmedmumps cases from Vojvodina reported
between January and June 2012 according to age groups.
doi:10.1371/journal.pone.0139815.g006
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The first mumps cases registered in AP Vojvodina were imported from Bosnia and Herze-
govina where a large outbreak of mumps was ongoing at the time [7,8]. Interestingly, the
sequences detected in Serbia were identical to a minor variant found only once among 57
strains reported from Bosnia and Herzegovina and no other identical sequences were found on
GenBank. Further epidemiological investigation showed that the first patients came from the
Republika Srpska in Bosnia and Herzegovina, from where no mumps strain information
became available despite about 7700 registered cases during the 2011/2012 outbreak [7].
The complication rate at least early during the outbreak (13/119, 10.9%) [9] was slightly
higher than previously reported [16,24,25], possibly because of the high numbers of affected
postpubertal males. The more important disease complications in males [26] may also explain
why overall twice as many male than female cases were reported.
In summary, the present outbreak may in part be due to vaccine failures, one dose immuni-
zation policy at the start of the mumps immunization programme, vaccine shortage between
1999 and 2002 and facilitated virus spread in high school and university settings. It is unclear
whether additional factors such as vaccine cold chain breaches, differences in antibody titer
and waning related to the vaccine used or genotypic mismatches between the vaccine strain
and wildtype viruses circulating in the population played a role. Mumps outbreaks in vacci-
nated populations raise the issue of vaccine efficacy, and duration and robustness of protection.
The reshuffling of birth cohorts with different levels of immunity warrants additional vaccina-
tion opportunities especially for young people at the transition of their life trajectories.
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